Publication: Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in β-thalassemia
Issued Date
2009-07-20
Resource Type
ISSN
10292470
10715762
10715762
Other identifier(s)
2-s2.0-67650175472
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Free Radical Research. Vol.43, No.5 (2009), 485-491
Suggested Citation
Totsapol Jirasomprasert, Noppawan Phumala Morales, Lie M G Limenta, Srisuporn Sirijaroonwong, Paveena Yamanont, Prapin Wilairat, Suthat Fucharoen, Udom Chantharaksri Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in β-thalassemia. Free Radical Research. Vol.43, No.5 (2009), 485-491. doi:10.1080/10715760902870611 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/27177
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in β-thalassemia
Abstract
The potential of free radical formation in serum of β-thalassemia/ Hb E patients receiving a single oral dose of 25 mg/kg body weight of deferiprone, a bidentate orally active iron chelator, was evaluated using EPR/spin trapping technique. In the presence of ascorbic acid and tert-butylhydroperoxide, EPR signals of ascorbyl radical (aH= 0.18 mT) and DMPO-carbon centred adduct (aH= 2.37 mT, aN= 1.65 mT) were detected. Shortly after deferiprone administration, EPR signal intensities decreased concomitant with an increase in serum levels of deferiprone. Unfortunately, enhanced EPR signal intensities were observed at 300 min after dosing in patients with serum molar ratio of deferiprone to iron less than 3, suggesting the formation of incomplete iron-deferiprone complexes and consequently free radical formation. To avoid adverse effects of deferiprone, a dosage regimen should be designed according to iron status of the patients and aimed at maintaining an adequate ratio of serum chelator-to-iron concentration.